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A monoclonal antibody (1G1O) recognizes a novel human
mesangial antigen
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A monoclonal antibody (1G1O) recognizes a novel human mesangial
antigen. We have identified a unique mesangial matrix protein of the
human glomerulus by using a monoclonal antibody, 1010, generated
against cultured human glomerular cells. By immunofluorescence, the
antigen recognized by 1G1O (IGlO antigen) is present in mesangium and
smooth muscle tissue and cannot be detected in any other tissue
examined. Immunoelectron microscopy of glomeruli indicated that
1010 antigen is present exclusively in the mesangial matrix at the
endothelial-mesangial interface. The lGlO antigen is also expressed by
cultured mesangial cells, but not by cultured glomerular epithelial cells,
umbilical endothelial cells or fibroblasts. 1010 did not react with the
mesangial matrix proteins [fibronectin (FN), laminin (LAM), collagen
types I, III, IV, V, and VI (Col I, III, IV, V, VI), heparin sulfate
proteoglycan (HSPG), or thrombospondin (TS)] present under normal
and diseased states or smooth muscle antigens (myosin, actin), but did
react with a 4 M urea extract of renal cortex and a 0.3% deoxycholate
extract of isolated glomeruli. Two dimensional immunoblot analysis
using the urea extract demonstrated the binding of 1Gb to an —200
KDa polypeptide with p16.0. On one dimensional immunoblot this band
did not show cross react with polyclonal antisera to FN, LAM, Col IV,
V, VI, HSPG or TS. This mesangial matrix component is trypsin and
periodate sensitive, suggesting that it has the character of glycoprotein.
In renal biopsy specimens from patients with mesangial proliferative
gbomerulonephritis (GN) and membranoproliferative GN, the expres-
sion of the lGlO antigen increased along with mesangial hypercellular-
ity or increased accumulation of mesangial matrix, but decreased in
completely sclerosed glomeruli. No significant changes in 1010 antigen
expression was observed in membranous GN or minimal change
nephrosis compared to normal glomeruli. This study suggests that the
1010 antigen may not only be a useful marker for the clinical assess-
ment of GN, but may also serve as a potential tool for the study of the
pathogenesis of glomerular diseases characterized by cellular prolifer-
ation and mesangial matrix expansion.
The glomerular mesangium, which is composed of smooth
muscle (SM)-like cells, mesangial cells (MCs) and an intercel-
lular material, mesangial matrix (MM), is a prominent site of
morphological change in many forms of human glomerulone-
phritis (GN). Marked expansion of the MM, with or without an
increased number of MCs, is a hallmark of progressive glomer-
ular diseases and leads to the glomerular sclerosis which is the
most common histological feature of end-stage kidney diseases.
Recent biochemical and immunohistochemical studies on
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extracellular matrix (ECM), and the advent of glomerular cell
culture technique, have markedly expanded our understanding
of the components, function and cell biology of the mesangium
in normal and diseased states [1—3]. The MM contains several
glycoproteins, including types IV, V, and VI collagen (Col, IV,
V, VI), fibronectin (FN), laminin (LAM), thrombospondin
(TS), and a variety of proteoglycans. Excessive accumulation
of these mesangial ECM components is characteristic of ad-
vanced glomerular diseases, such as chronic GN and diabetic
nephropathy [4—9]. Cultured MCs have been demonstrated to
produce not only above ECM components but also Col I and
Col III, which are not found in normal mesangium but are
detectable in disease states [10, Il]. Interestingly, MCs in
prolonged culture form MC hillocks which are similar in com-
position and organization to the sclerotic mesangial lesions
found in various forms of human GN [12].
Based on these findings, it seems likely that disregulation of
ECM formation by MC may lead to functional and morpholog-
ical alterations of the mesangium with overdeposition of MM
components. It is therefore important to clarify the precise
contribution of MC-derived ECM products to the process of
MM accumulation in diseased glomeruli. Clinically, it has
proven difficult to define the contribution of MCs to the
accumulation of excess mesangial ECM because of the diffi-
culty in differentiating the various ECM products of different
glomerular cells (MCs, endothelial and epithelial cells) and of
extraglomerular cells, such as invading fibroblasts in renal
tissue sections. Identification of MM molecules produced only
by glomerular MCs could allow us to study MC behavior in
human GN and may provide useful tools for clinical assessment
of the stage and prognosis of glomerular diseases.
In this study, we report the production of a mouse monoclo-
nal antibody (MAb), 1Gb, recognizing a novel, —-200 KDa,
mesangial glycoprotein presumed to be produced only by MCs,
and examine the distribution of the 1G1O antigen in the mesan-
gial injuries observed in several glomerular diseases.
Methods
Cell cultures
Human kidneys were obtained at the time of nephrectomy for
neoplasia. Glomeruli were isolated from decapsulated kidneys
by a sieving method as previously described [13]. Glomeruli
treated with 0.25% trypsin were seeded onto plastic flasks and
maintained at 37°C in an atmosphere of 95% air and 5% CO2 in
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Fig. 1. Binding pattern of 1GIO to human kidney (a) and human cultured mesangial cells (b). Diffuse staining by 1GIO is found in the glomerular
mesangium (a, x 600) and on mesangial cells with their extracellular products (b, X 300).
Fig. 2. Distribution of IGJO antigen in normal human tissues. 1G10 binding is detected in the smooth muscle layers of small intestine (a, x 60),
renal artery (b, x 100) and trabeculae of spleen (c, x 200). No lGl0 staining was seen in any other tissue examined.
RPM! 1640 medium supplemented with 20% decomplemented
fetal bovine serum (FBS, Gibco, Grand Island, New York,
USA). Subcultures were performed using 0.025% trypsin and
0.01% EDTA. The cultured glomerular cells, which were elon-
gated and formed multilayered sheets, were used for immuni-
zation between the third and sixth passages. Each cultured
glomerular cell was identified as either epithelial, or MC using
previously reported criteria [14], including phase-contrast mor-
phology, and specific immunofluorescence (IF) staining for
keratin and myosin. IF staining for factor VIII was always
negative on the cultured cells. Human fibroblasts were ex-
planted from surgically obtained skin specimens. Cultured
endothelial cells were derived from human umbilical vein tissue
as previously described [151. Cultured human fibroblasts and
endothelial cells used here were obtained from passage two to
five.
Production of MAb, IGIO
BALB/c mice were immunized three times by intraperitoneal
(i.p.) injections, at two week intervals, of the above human
glomerular cell cultures. Almost all (95%) of immunized gb-
merular cells showed the characteristics of MC but a small
minority (about 5%) of these cells had keratin filaments as a
marker of epithelial cell. Most of immunized cells also showed
prominent IF staining for ECM components such as FN, type
IV collagen. Immune spleen cells were fused with NS-1 (P3-
NS1/1-AG4-l) myeloma cells on day 3 after the third injection,
as previously described [16]. The lGlO(IgGl) hybridoma was
selected based on its positive immunostaining of both cryostat
human kidney sections and cultured MCs derived from human
glomeruli. The 1Gb clone was propagated and injected i.p. into
pristane primed BALB/c mice for ascites production. The MAb
was purified from ascites fluid by ammonium sulfate fractiona-
tion and protein G Sepharose affinity chromatography (Pharma-
cia Fine Chemical, Sweden), and was biotinylated for immuno-
histochemical use at 1 mglml in 0.1 M NaHCO3 (pH 8.0) using
a commercial biotinylation kit (Amersham, UK).
Immunohistochemistry
Immunofluorescence (IF) microscopy. The tissue specificity
of 1G1O was examined by indirect IF on cryostat sections of
human tissue samples from lung, liver, spleen, small intestine,
placenta, renal artery, thymus, lymph node, skin, striated
muscle, and cardiac muscle. The reactivity of 1GIO to various
cultured human cells (gbomerular mesangial, epithelial, umbili-
cal endothelial cells, and fibroblasts) was also tested by indirect
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Fig. 3. Ultrastructural localization of the IGIO antigen in the human glomerulus. The peroxidase reaction product (arrowheads) is observed it
the mesangial matrix at the endothelial-mesangial interface (x 10,000). MC; mesangial cell, En; endothelial cell,
0
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Fig. 4. Isolation of the IGIO antigen from a 4 M urea extract of human kidney. The IG1O antigen is recovered in the 0.3 M NaCI eluate (fr. 68—73),
as detected by immune dot assay.
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Fig. 6. Western blot of JGJO with fr. 70 of urea extract (UREA) and
DOC extract (DOC) under non-reducing (NR) or reducing (R) condi-
tions. The amount of protein per lane is 50 sg for urea extract samples
and 100 .tg for DOC extract samples. Molecular sizes are shown on the
left. IG1O labels —200-KDa band in UREA (lanes 1, 2) and DOC (lanes
3, 4) extracts.
TS
Fig. 5. Immune dot assay testing the reactivity of IGIO to DOC
extract, ECM components and vascular muscle antigen (actin, myo-
sin). Samples used here are as follow: 0.3% deoxycholate extract
(DOC), fibronectin (FN), laminin (LAM), collagen types I, III, IV, V,
and VI (COL, I, III, IV, V, VI), actin, myosin, heparan sulfate
proteoglycan (HSPG), and thrombospondin (TS). Note the positive
reaction of lGlO with DOC extract (5 pg/well) and the lack of specific
immunoreactivity with the other matrix components (10 sgIwell). A
culture supernatant of a murine hybridoma, RVGI (IgG 1), is used as a
negative control.
IF staining of cell monolayers grown on multi-chamber slide
glasses (Nunc, USA). Briefly, tissue sections and cultured cells
were fixed in cold acetone, and were reacted, successively,
with 1Gb culture supernatant (1 hr), and fluorescein-rabbit
anti-mouse IgG (Dako, Holland) (1 hr), which had been preab-
sorbed with normal human serum to avoid cross reactivity.
Immunoelectron microscopy (EM). 1G1O binding to kidney at
the ultrastructural level was studied using a pre-embedding
immunoperoxidase technique as previously described [161.
Control experiments included the incubation of the renal tissue
sections without primary antibody or with a mouse IgG 1 MAb
(RVG1), proven not to be reactive with human kidney. For the
positive control of the pre-embedding method, a mouse IgGi
MAb (OX-7) against rat Thy 1-1 antigen [17], was applied as the
primary antibody to rat renal tissue sections.
Biochemical treatment of tissue sections
To examine the effect of chemical or enzymatic treatments on
iGlO antigenic determinants, cryostat kidney sections were
treated with one of the following: 0.05% trypsin (Sigma, type
III, USA) in PBS for three hours; 1% sodium metaperiodate
(Wako, Japan) in PBS for 10 minutes; or 6 M urea in 0.1 M
glycine-HCI buffer, pH 3.5, for one hour. After incubation,
1G1O binding was tested by indirect IF as described above.
Biochemical characterization of the antigen recognized by
JG1O (IGJO antigen)
Extraction of JGJO antigen from human kidney for immune
blotting. Two methods were used to extract the iGlO antigen.
The success of extraction procedures was tested by immune dot
assay with 1Gb. In the first method, human renal cortical slices
were minced with a razor blade and homogenized. The homoge-
nates were centrifuged at 1,000 g for 10 minutes. Precipitated
material was extracted with 4 M urea in 50 mrvt Tris-HC1 buffer
(pH 7.3) containing 2 mrvi EDTA and 1 mrvt phenylmethylsulfo-
nyl fluoride (PMSF) (extraction buffer), stirred overnight at 4°C,
Kagami et al: A MAb recognizing a novel mesangial antigen 703
>
DOG
FN
200
LAM
COL. (I) 116
971
66
43
COL. (III)
COL. (IV)
COL. (V)
COL. (VI)
Actin
Myosin
HSPG
and then centrifuged at 16,000 g for 30 minutes. The supernatant
was applied to a column of DEAE-Sephacel (Pharmacia Fine
Chemical, Uppsala, Sweden) pre-equilibrated with the same
buffer. Stepwise elution was performed with 0.1 M, 0.3 M, and
0.5 M NaC1 in extraction buffer, Effluents were collected in 0.3
ml fractions and monitored by absorbance at 280 nm. In the
second method, human glomeruli were isolated by a sieving
method and were solubilized with 0.3% deoxycholate (DOC)
(Sigma, USA) in 50 mrsi Tris-HC1, 0.15 M NaC1 (pH 8.0), with 2
mM EDTA and 1 mrvi PMSF, for three hours at room temper-
ature. The supernatant after centrifugation at 16,000 g for 30
minutes was used for the immune dot assay.
Preparations of extracellular matrices and polyclonal antisera
Collagen types I, III, IV, V, and VI (ColT, III, IV, V, VI) and
laminin (LAM) from human placenta were purchased from
Fijiyakuhine Kogyou (Japan) and Chemicon International, Inc
(USA), respectively. Fibronectin (FN) was purified from cit-
rated human plasma by Engvall's method [18]. Thrombospon-
din (TS) was purified from human platelets by Lawler's method
Ll9]. Heparan sulfate proteoglycan (HSPG) from EHS sarcoma
was provided by Dr. K. Kimata (Institute for the Molecular
Science of Medicine, Aichi Medical University) [20]. Anti-Col
IV, V, and VI antisera (rabbit) were purchased from Advance,
Inc. (Japan). Anti-FN, LAM and TS antisera were produced by
immunization of rabbits with the products purified as above.
Anti-HSPG antisera (rabbit) was also provided by Dr. K.
Kimata. The specificity of these antisera was evaluated using
the immune dot assay. These antisera were shown to be active
against human glomerular mesangium by indirect IF on frozen
sections, using FITC-anti-rabbit IgG (Cappel Products, Coch-
ranville, Pennsylvania, USA) as a second antibody.
Immune dot assay
The reactivity of 1G1O to various known mesangial matrix
components, smooth muscle actin and myosin (rabbit, Sigma)
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Fig. 7. Cross reactivity of the 1GJO antigen
with polyclonal antisera to ECM components.
200 KD Western blots of urea extract samples (fr. 70,
50 g per lane) were probed with IG 10 (lane
1) and, polyclonal antisera to FN, LAM, Col
IV, V, VI, HSPG and TS (lanes 2—8). The
—200 KDa antigen detected by IGIO (lane 1)
was not detected by any other anti-ECM
1 2 3 4 5 6 7 8 antiserum (lanes 2—8).
pH
5.0 6.0 7.0 8.0
I I I I
200 —
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9 97—
66—
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Fig. 8. Two-dimensional Western blot of urea
extract (fr. 70) proved with 1Gb. Molecular
sizes are indicated on the left and pH above.
IGIO reacts with —-200 KDa band with a p1 of
6.0 (arrow).
/
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and extracted kidney proteins was assayed using the Bio-Dot
apparatus (Bio-Rad, Richmond, California, USA). Aliquots
(100 sl) of test proteins were dotted onto nitrocellulose (NC)
membranes (Bio-Rad), and dried for one hour. The membranes
were then blocked with 3% BSA in PBS (300 pA) for one hour
and exposed to 1G1O culture supernatants or to a control
supernatant of murine IgGi MAb (RVG1) for one hour. After
washing with 0.1% Tween 20-PBS, a peroxidase-laveled goat
antimouse IgG (Bio-Rad) was applied as a second antibody for
one hour. After wtshing, a color reaction was performed with
0.05% 4-chloro-l-naphtol and 0.03% hydrogen peroxide in PBS.
Electrophoresis and Western blot
Samples containing iGlO antigen were subsequently ana-
lyzed using one and two dimensional SDS-polyacrylamide gel
electrophoresis (SDS-PAGE), followed by Western blot.
Briefly, one dimensional electrophoresis was performed ac-
cording to the method of Laemmli [211 on gradient gels of 4 to
12% polyacrylamide. When desired, samples were reduced with
2% 2-mercaptoethanol. Molecular weight were calibrated from
a gel run simultaneously with protein standards (Bio-Rad). Two
dimensional electrophoresis using isoelectric focusing (IEF) in
the first dimension and 5 to 15% gradient SDS-PAGE in the
second dimension followed the method of O'Farrell [22]. To
determine the pH of the gradient formed in the first dimension,
a parallel IEF gel containing no proteins was sliced sequentially
into 2-mm sections, Each section was then equilibrated in a
capped tube with 100 pA of water and pH was measured using a
micro-pH-meter. After running the SDS-PAGE, protein bands
were transferred to NC membranes using a Sarto-blot apparatus
(Sartorius, Germany). Immunodetection with 1G1O was carried
out as described for the dot blot assay. Cross reactivities of the
polyclonal antisera against FN, LAM, Col IV, V, VI, HSPG
and TS to lGlO antigen were tested on one dimensional
immunoblot experiments. Bound rabbit antibody was detected
by a peroxidase-labeled goat anti-rabbit IgG (Cappel Products),
followed by the color reaction as above.
Patients
Fifty-seven renal biopsy specimens were examined in this
study. Pathological diagnosis was established using routine
light, IF and electron microscopy. These renal specimens
obtained from patients with histopathological diagnoses of
minimal change nephrotic syndrome (MCNS) in five cases,
mesangial proliferative glomerulonephritis (GN) (IgA GN in 25,
non-IgA GN in 11), membranoproliferative GN (MPGN) in five,
and membranous nephropathy (MN) in 11. Tissue sections were
stained using a biotinylated 1 G 10-FITC-labeled streptavidin
system (Amersham, UK).
Results
Immunohistochemical characterization of the IGJO antigen
In kidney sections examined by indirect IF, IG1O bound to
glomerular mesangium (Fig. la) and smooth muscle cells of
blood vessels. 1G1O also stained around smooth muscle cells
elsewhere in the body, reacting with the smooth muscle layer of
the gastrointestinal tract, of the trabeculae of spleen, and with
the medial layer of all blood vessels (Fig. 2). All other examined
tissues, including the endothelial cells of blood vessels, were
nonreactive. Neither skeletal nor cardiac muscle reacted with
the antibody, although 1G1O did recognize smooth muscle cells
of the blood vessels in these tissues. Pretreatment of human
tissue sections with acid urea to exclude the possibility of
antigen masking did not change the distribution of lG 10 stain-
ing. 1G1O therefore appears to be smooth muscle specific. The
lGlO binding to tissue sections was abolished by trypsin
digestion or periodate oxidation, suggesting that the 1G1O
antigen molecule has glycoprotein characteristics.
To identify the cells producing the lGlO antigen in the
glomerulus, we turned to cell culture. Until passage five, fast
growing MCs expressed 1G1O antigen detectable by indirect IF
(Fig. lb). Cultured glomerular epithelial cells, umbilical endo-
thelial cells and fibroblasts were all negative for the lGlO
antigen, as were late passage MCs. At the ultrastructural level,
lGlO reactivity was localized predominantly in the mesangial
matrix at the endothelial-mesangial interface, but was not
observed in the peripheral capillary loops (Fig. 3).
Biochemical characterization of the JGJO antigen
The iGlO antigen was extracted from human kidney by 4 M
urea treatment of renal cortex followed by DEAE chromatog-
raphy or by DOC treatment of isolated glomeruli, and assayed
by immune dot (Figs. 4 and 5). The cross reactivity of 1G1O to
the known mesangial matrix proteins (FN, LAM, Col I, III, IV,
V, VI, HSPG, TS) present under normal and diseased states or
vascular smooth muscle antigens (actin, myosin) was examined
simultaneously in this assay, and no reactivity was found (Fig.
5). These proteins are thereby excluded as the target of 1Gb,
and did not carry a cross reacting epitope. Western blot analysis
of the urea extract (fraction 70) and of the DOC extract under
nonreducing and reducing conditions showed that lGlO reacted
with an —200 KDa band (Fig. 6). There was no binding of
control MAb. We also tested the reactivity of rabbit polyclonal
antisera against FN, LAM, Col IV, V, VI, HSPG and TS with
the —200 KDa polypeptide recognized by lGlO on Western
blots (Fig. 7). None of test antibodies reacted to the lGlO
stained band. These data suggest that the 1G1O antigen is
immunologically unrelated to these defined mesangial antigens.
To examine the character of the 1G1O antigen further, frac-
tion 70 of the urea extract was analyzed by two-dimensional
immunoblotting. As shown in Figure 8, the protein detected by
lGlO has a molecular wt of —200 KDa and p1 of 6.0.
Expression of 1Gb antigen in the kidney in human
glomerular disease
The expression of lGlO antigen was studied in kidney spec-
imens from patients with various gbomerular diseases. In
mesangial proliferative GN (IgA GN and non-IgA GN) and
MPGN, increased mesangial expression of lGlO antigen cone-
bated with the increase in the mesangial matrix and mesangial
cell number, whereas the expression in MN and MCNS was
similar to that in normal gbomeruli (Fig. 9 a and b). Completely
sclerosed gbomeruli reacted only weakly with lGlO (Fig. 9c).
Although the interstitial localization of lGlO antigen is re-
stricted to the smooth muscle cells of blood vessels in normal
kidney, it tended to be detectable in the periglomerular regions
of patients with proliferative GN (Fig. 9b). Immuno-EM exam-
ination of the periglomerular area of these patients showed that
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Fig. 9. Glomerular expression of IGIO antigen in kidney Sections of patients with mesangial proliferative (IgA) glomerulonepritis. An increased
amount of 1Gb antigen was observed in the mesangial area (a, x 600, b, x 400), corresponding to mesangial hypercellularity (d, x 600) or to an
accumulation of mesangial matrix (e, x 800). A weak, fine granular distribution of 1Gb antigen (c, X 800) was present within a completely
scierosing glomerulus (f, x 800). Note the positive staining with IGIO in perigbomerular regions (b). Bright field view (PAS staining) of each kidney
specimen is to the right of the dark field view of 1010 staining. Immuno-EM of the periglomerular area, as shown in b, shows that IG1O antigen
is irregularly localized on the interstitial collagen fibers, but not present in the parietal epithelial cells of the glomerulus (g, x 3,600). Abbreviations
are: BS, Bowman's space; PC, peritubular capillary.
the 1G1O antigen was irregularly present on the interstitial
collagen fibers, but not expressed in the parietal epithelial cells
of the glomerulus (Fig. 9g).
Discussion
One of the major problems encountered in the understanding
of the pathogenesis of glomerulosclerosis is the lack of markers
of MC activity, which is thought to play a key role in the
initiation and evolution of the sclerotic process [4, 23]. In
particular, the assessment of the secretory profiles of MCs at
the site of accumulation of excess mesangial ECM remains
speculative in the absence of such specific markers.
In this paper, we have reported the discovery and character-
ization of a novel mesangial matrix component, the 1G1O
antigen, with an apparent molecular wt of 200 KDa, which was
present in all smooth muscle tissues examined by immunohis-
tochemistry, but not in any other tissues. It is well known that
some ECM protein antigens may be hidden by their interaction
with other tissue components, but can be exposed for immuno-
detection by treatment with acid urea [24]. In our study,
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however, acid urea treatment failed to reveal any 1010 antigen
in other tissues, suggesting that our observation may represent
the true distribution of this molecule.
The very limited tissue distribution of the 1GIO antigen
compared to that of other ubiquitous ECM components, and its
immunological independence from normal components of
mesangial ECM, including FN, LAM, Col IV, V, and VI,
HSPG and TS as well as Coil and III appearing under diseased
states, suggest that it is a novel matrix component. Data from
cell culture and histochemistry including immuno-EM suggest
that the iGlO antigen is produced only by MCs in the glomer-
ulus, and that it is subsequently incorporated into MM, specif-
ically in areas between endothelial cells and MCs. The spatial
restriction of the 1G1O antigen on tissue sections, compared to
its diffuse expression in cultured MCs, is not an artifact of
unique antigen access in fixed tissue sections, since simulta-
neous immuno-EM using a MAID, OX-7, against the rat mesan-
gial Thy-i-i antigen showed diffuse immunolocalization every-
where on the surface of mesangial MCs. The localization of the
1GIO antigen, therefore, may reflect its specific molecular
function in the glomerulus.
The similarity of MCs and smooth muscle cells (SMCs) in
terms of their origin and their functional and structural charac-
teristics [251, and the early disappearance of 1010 antigen from
MCs in culture both suggest that the lGiO antigen expressed by
both cell types may be a SMC-specific ECM molecule, support-
ing the concept that MCs have the character of SMCs in vivo.
Among other SM tissue specific proteins, the 1PC1 antigen,
described by Lamaziere et a!, is not only present in both SM
tissue and MCs in vivo in rabbit, but is also secreted from
cultured SMCs [26]. Interestingly, this antigen was also identi-
fied by using a MAb, 1PC1 obtained by immunizing mice with
cultured rabbit SMCs. These results also suggest that MCs and
SMCs both synthesize identical and specific ECM proteins in
vivo. Although direct investigation with the two MAbs (1G1O
and 1PC1) will be necessary to determine whether they recog-
nize related molecules, lPCl detects a non-reduced component
of molecular wt 350 KDa (170 KDa in a reduced form) from
extracts of cultured SMCs on immunoblots, which clearly differ
from the --200 KDa band detected by iGiO in our experiments.
Most strikingly, the expression of the 1010 antigen in mesan-
gium increased along with the level of cellularity and ECM
accumulation in diffuse mesangial proliferative ON (both of the
IgA and non-IgA types) and in MPGN, while it decreased in the
completely scierosed glomeruli in the above disorders. In
nonproliferative disorders such as MN and MCNS, glomerular
expression of the 1G1O antigen resembles that in normal gb-
meruli. These observations may be particularly significant in
the study of the relationship of MCs to the structural alterations
of mesangial pathology, since the change of expression of the
1010 antigen seems to directly reflect MC behaviors including
proliferation and ECM formation. The extensive use of poly-
cbonal or monoclonal antibodies against various ECM and
cytoskeletal components in kidney disease has not yet allowed
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precise characterizations of MCs in diseased glomeruli, because
the antigens they produce are shared by several glomerular cell
types so that changes in antigen distribution are not always
correlated with mesangial alterations on histological examina-
tion [4—10, 271. Thus, the IG1O antigen may present a uniquely
specific marker of MC activity in both physiological and patho-
logical conditions of the mesangium.
In addition to the changes in the mesangial distribution of the
1G1O antigen in glomerular diseases, we also frequently ob-
served an interstitial immunoreactivity with 1Gb in patients
with proliferative GN. Although the mechanism of the appear-
ance of the 1G1O antigen in the interstitium is unknown, our
findings suggest at least two possibilities. The first is that the
1G1O antigen accumulation in the mesangium of mesangial
proliferative GN spills through the vascular pole into the
interstitium around diseased glomeruli. Another possibility is
that the synthesis of the 1G1O antigen occurs in situ. It is
tempting to speculate that interstitial cells, principally fibro-
blasts, begin to express the biosynthetic profile of SMCs due to
some stimuli of the pathological states. Fibroblastic cells in
kidney fibrosis have been found to exhibit the morphological
and immunoreactive properties of SMCs by Nagle et al [28] and
Scheinman, Fish and Michael [27]. Indeed, it is well known that
fibroblastic cells come to express a repertoire of muscle cell
features in pathologic settings characterized by tissue remodel-
ing and fibrosis [29].
Conclusive evidence of the SMC specificity of the iGlO
antigen will require the development of polyclonal antibodies to
an affinity-purified antigen for immunohistochemistry and, most
importantly, the cloning of the gene for the antigen to allow
analysis of gene expression by Nothern blotting and in situ
hybridization. However, the results of our studies at least
suggest that the lGlO antigen may serve as a unique marker for
identification of MC activity in physiological and pathological
states, perhaps because it mediates an MC-specific function in
the area between MCs and endothelial cells in the glomerulus.
Detailed analysis of the lGlO antigen may ultimately increase
our understanding of the role that the MC plays both in normal
mesangial function and in the pathogenesis of glomerular scle-
rosis.
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